What is the clinical and cost effectiveness of N-terminus pro-B-type natriuretic peptide (NT-proBNP) compared to B-type natriuretic peptide (BNP) in people with suspected heart failure who also have chronic kidney disease, when each is followed by the appropriate patient pathway, in order to improve patient outcomes?
N-terminus pro-B-type natriuretic peptide (NT-proBNP) has been shown to be clinically and cost effective for people with suspected heart failure who have chronic kidney disease, when followed by the appropriate patient pathway, in order to improve patient outcomes. Studies have shown that NT-proBNP can be used to identify patients with heart failure and that it is cost-effective when used in combination with BNP in the diagnosis and management of patients with heart failure. NT-proBNP has also been found to be superior to BNP in predicting mortality and readmission rates in patients with heart failure and chronic kidney disease.